Can brentuximab vedotin and nivolumab cause alopecia?

Can Brentuximab Vedotin and Nivolumab Cause Alopecia?

Yes, both brentuximab vedotin and nivolumab can cause alopecia, though the risk and patterns differ between the two agents.

Brentuximab Vedotin and Alopecia

Brentuximab vedotin is clearly associated with alopecia as a common adverse effect. According to FDA labeling, alopecia occurs in ≥20% of patients receiving brentuximab in combination with chemotherapy 1. A meta-analysis of randomized controlled trials confirmed that brentuximab significantly increases the risk of all-grade alopecia (RR 1.18,95% CI: 1.00-1.39) compared to non-brentuximab regimens 2.

Key points about brentuximab-related alopecia:

• Occurs commonly (≥20%) when used in combination therapy
• Typically non-scarring and reversible
• Listed as an expected adverse reaction in FDA labeling
• Does not usually require treatment discontinuation

Nivolumab and Alopecia

Nivolumab can cause alopecia, but it is much less common and occurs through an immune-mediated mechanism. According to ESMO guidelines, alopecia areata is a rare immune-related adverse event with checkpoint inhibitors like nivolumab, though it is underreported because patients don't routinely undergo full dermatologic examination 3.

Critical characteristics of nivolumab-related alopecia:

• Can present as alopecia areata or even alopecia universalis (complete body hair loss) 4
• May occur late in treatment, not just early—one case developed after 11 months of therapy 4
• Can be scarring (lichen planopilaris pattern), which is permanent 5
• Represents an immune-mediated adverse event, distinct from chemotherapy-induced hair loss
• May paradoxically correlate with treatment response 4

Clinical Management Algorithm

For brentuximab-related alopecia:

• Counsel patients preemptively about expected hair loss
• No specific intervention required beyond supportive care
• Hair typically regrows after treatment completion
• Does not require dose modification

For nivolumab-related alopecia:

1. Distinguish the pattern: Determine if non-scarring (alopecia areata) vs. scarring (lichen planopilaris) through scalp examination and biopsy if needed 5
2. Grade severity: Assess extent and impact on quality of life
3. For non-scarring alopecia areata:
   • Topical corticosteroids may be attempted but often ineffective 4
   • Consider systemic immunosuppression only if severe and distressing
   • Weigh against oncologic benefit—many patients continue therapy despite alopecia 4
4. For scarring alopecia: Early intervention is critical to prevent permanent follicular destruction 5

Important Caveats

Timing matters with nivolumab: Unlike typical chemotherapy-induced alopecia that occurs early, immune-mediated alopecia from nivolumab can develop months into treatment or even after achieving remission 4. Maintain vigilance throughout the treatment course.

Scarring vs. non-scarring distinction is crucial: Scarring alopecia (lichen planopilaris) requires urgent dermatologic evaluation and aggressive management to prevent irreversible hair loss 5. This is a rare but serious complication that demands prompt recognition.

Consider the risk-benefit ratio: Given that immune-related adverse events may correlate with treatment efficacy 4, discontinuing nivolumab solely for alopecia should be carefully weighed against oncologic benefit, particularly when disease response is favorable.